Nordic Nanovector - Appointment of Alf Bjørseth as CEO

28 Jun 2023
www.prnewswire.com
Executive Change
OSLO, Norway, June 28, 2023 /PRNewswire/ -- Reference is made to the stock exchange announcement made earlier today by Nordic Nanovector ASA ("
Company"), where the Company announced, among other things, that the annual general meeting had elected new board members to the board of directors, including electing former interim CFO & CEO Ludvik Sandnes as new chairman.
Against this background, the board of directors of Nordic Nanovector has today appointed Mr. Alf Bjørnseth as new chief executive officer of Nordic Nanovector. The appointment will be effective as of today. Under Mr. Bjørnseth's employment agreement with the Company, his remuneration comprises of a cash compensation whereby at least half of the cash compensation shall be converted into restricted share units ("RSU's") in the Company. The number of RSUs to be granted by the board of directors to Mr. Bjørnseth shall be determined based on the average trading price of the Company's shares over the 10 days up to and including 27 June 2023.
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Ludvik Sandnes, Interim CEO & CFO
Cell: +47 907 43 017
Email: [email protected]
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.